Auswahl der wissenschaftlichen Literatur zum Thema „Vessie hyperactive“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Inhaltsverzeichnis
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Vessie hyperactive" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Vessie hyperactive"
Geoffrion, Roxana, Danny Lovatsis, Jens-Erik Walter, Queena Chou, William Easton, Annette Epp, Roxana Geoffrion et al. „Traitements visant la vessie hyperactive : Accent sur la pharmacothérapie“. Journal of Obstetrics and Gynaecology Canada 34, Nr. 11 (November 2012): 1102–4. http://dx.doi.org/10.1016/s1701-2163(16)35441-x.
Der volle Inhalt der QuelleGeoffrion, Roxana. „Traitements visant la vessie hyperactive : Accent sur la pharmacothérapie“. Journal of Obstetrics and Gynaecology Canada 38, Nr. 12 (Dezember 2016): S158—S170. http://dx.doi.org/10.1016/j.jogc.2016.09.027.
Der volle Inhalt der QuelleGeoffrion, Roxana. „N o 283-Traitements visant la vessie hyperactive : Accent sur la pharmacothérapie“. Journal of Obstetrics and Gynaecology Canada 40, Nr. 1 (Januar 2018): e33-e44. http://dx.doi.org/10.1016/j.jogc.2017.11.006.
Der volle Inhalt der QuelleBolduc, S., A. Fortin, V. Morin und P. Gervais. „P-032 – Observance au traitement chez les enfants atteints de vessie hyperactive“. Archives de Pédiatrie 22, Nr. 5 (Mai 2015): 241. http://dx.doi.org/10.1016/s0929-693x(15)30217-7.
Der volle Inhalt der QuelleGeoffrion, Roxana. „N o 353 – Traitements visant la vessie hyperactive : Accent sur la pharmacothérapie – Addenda“. Journal of Obstetrics and Gynaecology Canada 39, Nr. 12 (Dezember 2017): 1230–39. http://dx.doi.org/10.1016/j.jogc.2017.08.042.
Der volle Inhalt der QuelleZenner-Weber, Marietta. „Les symptômes d’urgence mictionnelle en cas de vessie hyperactive ont un retentissement considérable sur la qualité de vie“. Revue Médicale Suisse 5, Nr. 196 (2009): 687. http://dx.doi.org/10.53738/revmed.2009.5.196.0687.
Der volle Inhalt der QuelleLeon, P., A. Binet, C. Jolly und M. L. Poli-Merol. „Usage de la toxine botulique dans les vessies hyperactives non neurologiques chez l’enfant“. Progrès en Urologie 22, Nr. 13 (November 2012): 758. http://dx.doi.org/10.1016/j.purol.2012.08.041.
Der volle Inhalt der QuelleDenys, P., E. Chartier-Kastler, P. Azouvi, O. Remy-Neris und B. Bussel. „Effet urodynamique de la neurostimulation S3 test sur les vessies hyperactives résistantes des blessés médullaires“. Annales de Réadaptation et de Médecine Physique 41, Nr. 6 (Januar 1998): 348. http://dx.doi.org/10.1016/s0168-6054(98)80142-6.
Der volle Inhalt der QuelleAmarenco, G., A. Le Cocquen, D. Lagauche, M. Chevignard und S. Bosc. „Étude cystomanométrique de 153 vessies neurologiques hyperactives avant et après test au bromure de prifinium“. Annales de Réadaptation et de Médecine Physique 41, Nr. 7 (Januar 1998): 417–20. http://dx.doi.org/10.1016/s0168-6054(98)80263-8.
Der volle Inhalt der QuelleLardon, Renaud, und Alain Ruffion. „Quelles peuvent être les futures applications de la toxine botulique en urologie en dehors des vessies hyperactives des patients neurologiques ?“ Progrès en Urologie - FMC 19, Nr. 3 (September 2009): F91—F94. http://dx.doi.org/10.1016/j.fpurol.2009.02.003.
Der volle Inhalt der QuelleDissertationen zum Thema "Vessie hyperactive"
Biardeau, Xavier. „Optimisation des thérapies de stimulation/modulation électrique dans le traitement des troubles vésico-sphinctériens neurogènes et non-neurogènes“. Electronic Thesis or Diss., Université de Lille (2022-....), 2024. http://www.theses.fr/2024ULILS014.
Der volle Inhalt der QuelleEven if it involves alternating between a filling phase and an emptying phase, the normal micturition cycle cannot be summed up as a binary operation but involves the constant consideration of multiple factors: the filling level of the bladder reservoir, the safety of the environment in which we live, the emotional context in which we evolve and the social constraints to which we are subjected.We now know that there are alterations and/or modifications in brain activity and connectivity, as well as changes in the regulation of the autonomic nervous system, in certain types of lower urinary tract dysfunction - notably in overactive bladder or urge urinary incontinence and in certain types of voiding dysfunctions. Among the therapies available today, electrical modulation/stimulation therapies (tibial neurostimulation and sacral neuromodulation) appear able to normalize and/or modify brain activity and connectivity, as well as ANS balance. They could thus provide at least a partial response to some of the etiopathogenies underlying these lower urinary tract dysfunctions. However, the deployment and positioning of these electrical modulation/stimulation therapies are still limited by an incomplete understanding of their mechanisms of action, imperfect identification of the indications and populations most likely to benefit from these therapies, a lack of consensus on the setting of the electrical current delivered, and a lack of medium and long-term evaluation. In the first part, we questioned the indications for these therapies, and particularly their place as a preventive approach for lower urinary tract dysfunctions due to spinal cord injury. We also questioned the relation, in terms of efficacy, between transcutaneous tibial neurostimulation and sacral neuromodulation, to better support patients in shared medical decision-making processe. Finally, we developed the first tool to predict the success of sacral neuromodulation as a treatment for voiding dysfunction. In the second part, we questioned the mechanisms of action, and more specifically the changes in the balance of the autonomic nervous system in response to an acute S3 sacral root stimulation.In the third part, we questioned the mid-term follow-up (5 years) after definitive implantation of sacral neuromodulation in a geographic population pool, looking for risk factors for discontinuation of follow-up. These data, although still to be supplemented by future research projects, will enable us to further optimize electrical modulation/stimulation therapies in the management of neurogenic and non-neurogenic lower urinary tract dysfunctions